Home
Rune Nielsen's picture

Rune Nielsen

Associate Professor
  • E-mailRune.Nielsen@uib.no
  • Phone+47 55 97 29 48
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis. Microbiome. 1-11.
  • Show author(s) (2022). The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease . PLOS ONE.
  • Show author(s) (2022). Factors associated with coronary heart disease in COPD patients and controls. PLOS ONE. 1-17.
  • Show author(s) (2022). ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal. 19 pages.
  • Show author(s) (2022). A longitudinal study of the pulmonary mycobiome in subjects with and without chronic obstructive pulmonary disease. PLOS ONE.
  • Show author(s) (2021). The pulmonary mycobiome—A study of subjects with and without chronic obstructive pulmonary disease. PLOS ONE. 16 pages.
  • Show author(s) (2021). Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time. PLOS ONE. 1-14.
  • Show author(s) (2021). Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable? BMC Pulmonary Medicine. 1-12.
  • Show author(s) (2021). Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. American Journal of Respiratory and Critical Care Medicine. 1353-1365.
  • Show author(s) (2021). Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics. 15 pages.
  • Show author(s) (2021). Chronic airflow obstruction and ambient particulate air pollution. Thorax. 1236-1241.
  • Show author(s) (2021). Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status. World Allergy Organization Journal. 16 pages.
  • Show author(s) (2020). Respiratory symptoms and mortality in four general population cohorts over 45 years. Respiratory Medicine.
  • Show author(s) (2020). Incremental costs of COPD exacerbations in GOLD stage 2+ COPD in ever-smokers of a general population. Respiratory Medicine: X. 1-7.
  • Show author(s) (2020). Complications and discomfort after research bronchoscopy in the MicroCOPD study. BMJ Open Respiratory Research.
  • Show author(s) (2020). Coagulation markers as predictors for clinical events in COPD. Respirology (Carlton South. Print). 1-10.
  • Show author(s) (2020). Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without a history of asthma. European Clinical Respiratory Journal. 1-9.
  • Show author(s) (2019). Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. PLOS ONE. 1-18.
  • Show author(s) (2019). Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study. Respiratory Medicine. 81-88.
  • Show author(s) (2019). Pharmacological treatment of asthma in a cohort of adults during a 20-year period: Results from the european community respiratory health survey I, II and III. European Respiratory Journal Open Research (ERJ Open Research). 12 pages.
  • Show author(s) (2019). Motivation and response rates in bronchoscopy studies. Multidisciplinary Respiratory Medicine. 1-9.
  • Show author(s) (2019). Laboratory contamination in airway microbiome studies. BMC Microbiology. 1-13.
  • Show author(s) (2019). Determinants of fractional exhaled nitric oxide in healthy men and women from the European Community Respiratory Health Survey III. Clinical and Experimental Allergy. 969-979.
  • Show author(s) (2018). Guideline adherence in hospital recruited and population based COPD patients. BMC Pulmonary Medicine. 1-9.
  • Show author(s) (2017). Unemployment in chronic airflow obstruction around the world: Results from the BOLD study. European Respiratory Journal. 1-12.
  • Show author(s) (2017). Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD. European Respiratory Journal. 1-10.
  • Show author(s) (2017). Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respiratory Research. 1-9.
  • Show author(s) (2016). Macrophage migration inhibitory factor, a role in COPD. American Journal of Physiology - Lung cellular and Molecular Physiology. L1-L7.
  • Show author(s) (2016). Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients. The International Journal of Chronic Obstructive Pulmonary Disease. 2099-2108.
  • Show author(s) (2014). Productivity losses in chronic obstructive pulmonary disease: a population-based survey. BMJ Open Respiratory Research. 1-8.
  • Show author(s) (2014). Predictors of exacerbations in chronic obstructive pulmonary disease - results from the Bergen COPD Cohort Study. PLOS ONE.
  • Show author(s) (2014). Predictors of dyspnoea prevalence: Results from the BOLD study. European Respiratory Journal. 1610-1620.
  • Show author(s) (2013). The impact of COPD on health status: findings from the BOLD study. European Respiratory Journal. 1472-1483.
  • Show author(s) (2013). Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine. 1709-1721.
  • Show author(s) (2011). Excessive costs of COPD in ever-smokers. A longitudinal community study. Respiratory Medicine. 485-493.
  • Show author(s) (2011). ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. European Respiratory Journal. 1029-1035.
  • Show author(s) (2009). Present and future costs of COPD in Iceland and Norway: results from the BOLD study. European Respiratory Journal. 850-857.
  • Show author(s) (2009). Aspects of healthcare utilisation in self-reported obstructive lung disease. Clinical Respiratory Journal. 34-41.
  • Show author(s) (2008). Repeatability of health economic data in COPD. Respiratory Medicine. 1556-1562.
  • Show author(s) (2008). Economics of COPD: literature review and experiences from field work. Clinical Respiratory Journal. 104-110.
  • Show author(s) (2005). Leger i såpeoperaen – en studie av Akutten. Tidsskrift for Den norske legeforening. 3464-3467.
Reader opinion piece
  • Show author(s) (2013). Sex-related differences in respiratory symptoms: results from the BOLD Study. European Respiratory Journal. 858-860.
Doctoral dissertation
  • Show author(s) (2011). Costs of chronic obstructive pulmonary disease in a general population.
Abstract
  • Show author(s) (2020). Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD. European Respiratory Journal.
  • Show author(s) (2020). Changes in the induced sputum proteome during COPD exacerbations. European Respiratory Journal.
  • Show author(s) (2019). Repeated bronchoscopy examination of the airway microbiome. European Respiratory Journal.
  • Show author(s) (2019). Alterations in sputum inflammatory markers during exacerbations for COPD patients with different stable state levels. European Respiratory Journal.
  • Show author(s) (2010). Gender-related differences in respiratory symptoms: Results from the international BOLD Study. Wiener Klinische Wochenschrift. A49-A49.
  • Show author(s) (2009). How expensive is comorbidity in COPD? Respiratory Medicine. S7-S7.
Poster
  • Show author(s) (2005). Airflow obstruction is associated with increased health care utilization in self-reported obstructive lung disease.
Academic literature review
  • Show author(s) (2016). Participation in research bronchoscopy: a literature review. European Clinical Respiratory Journal.
  • Show author(s) (2016). Complications and discomfort of bronchoscopy: a systematic review. European Clinical Respiratory Journal. 9 pages.

More information in national current research information system (CRIStin)